<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977766</url>
  </required_header>
  <id_info>
    <org_study_id>CPV 2.0-IPC 2018-054</org_study_id>
    <nct_id>NCT03977766</nct_id>
  </id_info>
  <brief_title>Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit</brief_title>
  <acronym>CPV2-0</acronym>
  <official_title>Feasibility of a Process of Digital Validation of Outpatients Chemotherapies in a Day Treatment Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of CPV 2.0 study is to evaluate a process of digital prevalidation of outpatients
      chemotherapy thanks to a numeric application. This digital tool is based on the combination
      of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common
      Terminology Criteria for Adverse Events (PRO-CTCAE) to a decisional algorithm.

      After cycle 1, chemotherapy digital prevalidation will be done with the help of a nurse for
      two consecutive cycles (cycles 2 and 3). Patients will then have to use to application by
      themselves for the two following cycles (cycles 4 and 5)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the digital application</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of prevalidation of the chemotherapy by the digital application compared to the number of corresponding validation of the chemotherapy by the physician</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>nurse then patient digital prevalidation of chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Outpatient Chemotherapy prevalidation will done
with the help of a nurse, using the digital application, for cycle 2 and 3.
by the patient alone, using the digital application, for cycle 4 and 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemotherapy prevalidation</intervention_name>
    <description>Outpatient Chemotherapy prevalidation will done
with the help of a nurse, using the digital application, for cycle 2 and 3.
by the patient alone, using the digital application, for cycle 4 and 5.</description>
    <arm_group_label>nurse then patient digital prevalidation of chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt;80 (if age&gt;70 years, a G8 score&gt;14 is required)

          -  ECOG&lt;3

          -  Pathology (solid tumor, in neoadjuvant, adjuvant or metastatic setting)

          -  Patient receiving an IV cytotoxic chemotherapy in a day treatlent unit for at least 5
             cycles, with at least an injection at day 1, day 8 and day 15

          -  Familiar with digital tools

        Exclusion Criteria:

          -  Emergency

          -  patient feeling unease with the use of a smartphone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loui Tassy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Genre, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>digital application</keyword>
  <keyword>outpatients chemotherapy</keyword>
  <keyword>chemotherapy validation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

